ArticleUpdates in surgery2025
Development and validation of a predictive model for tumor regression following neoadjuvant chemoradiotherapy in rectal cancer.
Article in Updates in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comment on: "Dual-center development and validation of an immunoinflammatory-based preoperative model for predicting postoperative cachexia in colorectal cancer".Updates in surgery · 2026Article
- Neoadjuvant therapy for pMMR/MSS locally advanced rectal cancer in the immunotherapy era: current landscape and future perspectives.Frontiers in oncology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The standard treatment for locally advanced rectal cancer (LARC) involves neoadjuvant chemoradiotherapy (nCRT) followed by surgery. While nCRT improves tumor downstaging and R0 resection rates, heterogeneous responses among patients necessitate predictive tools to identify poor responders. This study aimed to develop a predictive model for tumor regression after nCRT using baseline clinical indicators. We retrospectively analyzed LARC patients treated with nCRT and total mesorectal excision (TME) at the Second Affiliated Hospital of Nanchang University (2016-2020). Baseline clinical data, including laboratory tests, tumor markers, and MRI findings, were collected. Tumor regression was evaluated post-nCRT using the RECIST criteria. Multivariate logistic regression identified predictors, and a predictive model was constructed. Model performance was assessed via ROC curves, decision curve analysis (DCA), calibration curves, and tenfold cross-validation. Finally, perform external validation on the model. Among 158 patients, 98 achieved objective response (CR/PR; 62%), while 60 showed poor regression (SD/PD). Independent predictors of tumor regression included pretreatment tumor diameter (P < 0.001), interval to surgery post-nCRT (P = 0.006), D-dimer (P = 0.010), prognostic nutrition index (PNI, P = 0.035), carcinoembryonic antigen (CEA, P = 0.004), and extramural vascular invasion (EMVI, P = 0.026). The predictive model demonstrated an AUC of 0.84 (95% CI 0.780-0.899), sensitivity of 85.0%, and specificity of 72.4%. Calibration curves indicated high accuracy, and DCA confirmed clinical utility. External validation demonstrated the model's reasonably good predictive value (AUC = 0.864, 95% CI 0.787-0.879). Pretreatment tumor diameter, interval to surgery, D-dimer, PNI, CEA, and EMVI are independent predictors of tumor regression after nCRT. The proposed model effectively stratifies LARC patients, guiding personalized treatment decisions to optimize outcomes.
Indexed as
Identifiers
40810858What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.